Life Biosciences has shared new preclinical findings at the 12th Aging Research and Drug Discovery (ARDD) Meeting, showcasing promising progress for its Partial Epigenetic Reprogramming (PER) platform. According to the company, this novel approach uses three of the four Yamanaka factors (Oct4, Sox2, Klf4) to reset the epigenome of aged or damaged cells toward a younger, healthier state.
In a mouse model of metabolic dysfunction-associated steatohepatitis (MASH), the experimental therapy ER-300 reportedly improved various liver health biomarkers. The company said that ER-300 led to significant improvements in ALT, AST, total cholesterol, total bile acids, NAFLD scores, percentage of hepatocytes with lipid droplets, liver weight, and steatosis score.
In a separate non-human primate model of optic neuropathy (NAION), Life Biosciences claims that its candidate ER-100 restored methylation patterns alongside functional enrichment of neuronal regeneration pathways. The company said these data complement earlier findings demonstrating effective targeting of retinal ganglion cells and functional cellular restoration measured by pattern electroretinogram.
The company said that these results reinforce the cross-system therapeutic potential of its PER platform in addressing age-related diseases affecting multiple organs. It emphasized that while the development is still in early stages, ER-100 is on track to enter human trials in the first quarter of 2026 for two optic neuropathies.
In summary, according to Life Biosciences, the latest ARDD findings show that their PER platform via ER-300 and ER-100 may offer a versatile strategy for treating both ocular and liver age-related conditions.
